Connect with us

Technology

NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Published

on

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancerCorrelative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPICombination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results

ROCKVILLE, Md., June 3, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference.

NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated.

Key findings from NIT-110 include:

Pancreatic cancer – Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond.MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2].

These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments.

A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes.

Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies.

NeoImmuneTech’s CEO, Luke Oh, PhD, said: “We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market.”

Posters references:

Abstract #

Track

Poster board #

Title

2621 (Link)

Developmental Therapeutics -Immunotherapy

100

A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors

2563

(Link)

Developmental Therapeutics -Immunotherapy

42

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors

2043

(Link)

Central Nervous System Tumors

342

Expand and pull: a new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy

 

About Study NIT-110
NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts.

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1
[2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Osstem Implant Accelerates Innovation in India with ‘Denall TV’, a Digital Dental Education Hub

Published

on

By

Over the past two years since its launch in April 2024, Denall TV has become a core platform for digital dental education in India.Opened a dedicated Denall Studio in India in July 2025, strengthening live hands-on and professional training programs.Supporting the professional growth of clinicians through practical content, including ‘Master Courses’ and ‘Product Reviews’.

NEW DELHI and MUMBAI, India, June 15, 2026 /PRNewswire/ — Osstem Implant announced that its specialized dental education platform for the Indian market, ‘Denall TV’ (https://in.denall.com), is gaining significant traction among local practitioners, establishing itself as a vital hub for digital dental education in India.

 Building a Comprehensive Digital Clinical Education Environment

Since launching its first content in April 2024, Denall TV has continuously evolved to meet the needs of Indian clinicians. To provide more immersive and high-quality education, Osstem Implant established a dedicated Denall Studio in India in July 2025. This facility has enabled the creation of a systematic digital clinical education environment, overcoming geographical limitations for dentists across the country.

Providing High-Quality, Practice-Oriented Clinical Content

The platform focuses on promoting ‘Digital Dentistry’ through specialized ‘Digital Surgery’ education and providing accurate product information. Denall TV consistently uploads essential clinical content, including: Live Hands-on sessions, Practical Master Courses, Expert product reviews featuring items such as the T2 Plus and 122 Taper KIT, helping clinicians make informed decisions for their practices.

Strengthening Trust as a Strategic Education Partner

Professional clinical courses have become a major topic of interest among local medical professionals. Notably, the ‘Implant System Introduction’ lecture has surpassed 25,000 views, proving the platform’s high influence. This achievement signifies that Osstem Implant has successfully established itself as a trusted education partner in the Indian market, going beyond its role as a manufacturer.

Bridging Global Trends and Improving Educational Accessibility

Osstem Implant connects local practitioners with global academic networks. The platform provides timely content from global academic events such as the ‘2026 Osstem World Meeting in Bangkok’, sharing the latest implant trends and technological advancements with the Indian dental community. By offering online access, Denall TV effectively bridges the educational gap for dentists in regions where offline seminars are difficult to attend.

An official from Osstem Implant India stated, “Denall TV serves as a key bridge, delivering world-class clinical knowledge to local dentists. We will continue to strengthen our real-time interactive webinars to provide deeper clinical insights.” The official added, “We are committed to driving both the quantitative and qualitative growth of the Indian dental implant market through the continued provision of high-quality educational content.”

Moving forward, Osstem Implant plans to enhance its B2C PR strategies centered around the Denall TV platform and lead the popularization of digital dental treatment in India through close communication with local practitioners.

Photo – https://mma.prnewswire.com/media/2996512/image1.jpg

View original content:https://www.prnewswire.com/in/news-releases/osstem-implant-accelerates-innovation-in-india-with-denall-tv-a-digital-dental-education-hub-302796515.html

Continue Reading

Technology

Avalara’s Bhumika Kenjale Receives Excellence in AI-Driven Tax Automation Solutions 2026 Award

Published

on

By

Recognition honors leadership in AI-powered compliance innovation and contributions to the future of global tax automation

PUNE, India, June 15, 2026 /PRNewswire/ — Avalara, Inc., the agentic AI leader in global tax and compliance, is proud to announce that Bhumika Kenjale, Director of Indirect Tax, has been honored with the Excellence in AI-Driven Tax Automation Solutions 2026 award at the Bharat 2.0 Conclave. The award recognizes leaders driving AI-led transformation in tax and compliance through innovation, technical expertise, and strategic vision that is shaping the future of the industry.

“We are immensely proud of Bhumika and the impact she continues to have on the global tax and compliance landscape,” said Dulles Krishnan, General Manager of India Operations at Avalara. “Her ability to combine deep regulatory expertise with AI innovation reflects the very essence of Avalara’s mission. This recognition highlights her exceptional leadership and the meaningful contributions she has made for Avalara, our customers, and the broader tax and compliance community.”

Kenjale has been instrumental in building the AI-driven infrastructure that powers seamless global compliance. Under her leadership, Avalara’s India Tax Research and Technology Capability Centre has expanded significantly, operating on an AI-first model with advanced automation to deliver highly accurate tax content at scale.

She also serves as a global Co-Chair of Women of Avalara, Avalara’s employee resource group, championing opportunities for women in technology and ensuring the next generation of women see a clear path to technology leadership.

About Avalara
Avalara is the agentic AI platform for global tax and compliance. For more than two decades, Avalara has built one of the most expansive libraries of tax content and integrations in the industry, processing more than 54 billion transactions annually and supporting millions of businesses worldwide. The company’s purpose-built AI agents automate end-to-end compliance with greater precision, from tax calculations and return filings to exemption certificate management and beyond. For more information, visit Avalara.com.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/avalaras-bhumika-kenjale-receives-excellence-in-ai-driven-tax-automation-solutions-2026-award-302799625.html

Continue Reading

Technology

From Waste to Value: How Jereh Builds the Circular Ecosystem for Batteries

Published

on

By

YANTAI, China, June 14, 2026 /PRNewswire/ — As electric vehicles and energy storage systems scale globally, a critical challenge has emerged: how to manage millions of batteries at the end of their life cycle.

The EU Battery Regulation and similar frameworks are imposing stricter mandates for recycled material content, carbon footprint disclosure, and end-of-life responsibility. Battery recycling has evolved from an environmental compliance duty to a strategic cornerstone of critical material security, supply chain resilience, and the energy transition.

One question remains: can compliant battery recycling be both sustainable and commercially viable?

For Jereh, the answer lies in its intelligent battery recycling demonstration facility in Zhengzhou, China. Since commissioning, the plant has processed more than 15,000 tons of raw feedstock, maintained a utilization rate above 80%, and achieved profitability within its first year of operation. Both the black mass recovery rate and purity exceed 98%, while copper and aluminum separation efficiency reaches up to 96%, underscoring the viability of industrial-scale battery recycling.

This facility served as the validation platform for Jereh’s Lithium Battery Recycling Equipment 1.0. Building on real-world operating data, Jereh has developed its next-generation Lithium Battery Recycling Equipment 2.0 and introduced its LFP Cathode Material Regeneration Solution, further enhancing the value recovery of end-of-life batteries.

The upgraded 2.0 equipment increases single-line annual capacity by 50% while improving operational safety, efficiency, and environmental performance. Meanwhile, the LFP regeneration solution reduces processing costs by 40% through a dry physical process, achieves up to 95% stripping efficiency, eliminates wastewater discharge, and cuts carbon emissions by around 60%.

Beyond technology development, Jereh is expanding its global battery recycling footprint through localized partnerships across South Korea, Australia, Hungary, and the United States. Following the successful 1.0 validation in Zhengzhou, the 2.0 equipment in Guangzhou and Chongqing is expected to commence operations in the coming weeks, with plans for further deployment in overseas markets. Recently, Jereh also signed an agreement with Witthal Gulf to jointly develop a benchmark lithium battery recycling project in Abu Dhabi. The project marks another milestone in Jereh’s efforts to support the development of sustainable battery recycling infrastructure worldwide.

Jereh also contributes to the development of battery recycling standards and safety frameworks, supporting a more mature and transparent recycling ecosystem. For Jereh, the goal is clear: transform retired batteries from waste into valuable resources and help close the loop across the global battery value chain.

View original content to download multimedia:https://www.prnewswire.com/news-releases/from-waste-to-value-how-jereh-builds-the-circular-ecosystem-for-batteries-302799938.html

SOURCE Jereh Group

Continue Reading

Trending